GATA2

GATA2
Identifiers
AliasesGATA2, DCML, IMD21, MONOMAC, NFE1B, GATA binding protein 2
External IDsOMIM: 137295; MGI: 95662; HomoloGene: 32030; GeneCards: GATA2; OMA:GATA2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

2624

14461

Ensembl

ENSG00000179348

ENSMUSG00000015053

UniProt

P23769

O09100

RefSeq (mRNA)

NM_032638
NM_001145661
NM_001145662

NM_008090
NM_001355253

RefSeq (protein)

NP_001139133
NP_001139134
NP_116027

NP_032116
NP_001342182

Location (UCSC)Chr 3: 128.48 – 128.49 MbChr 6: 88.17 – 88.18 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

GATA2 or GATA-binding factor 2 is a transcription factor, i.e. a nuclear protein which regulates the expression of genes. It regulates many genes that are critical for the embryonic development, self-renewal, maintenance, and functionality of blood-forming, lymphatic system-forming, and other tissue-forming stem cells. GATA2 is encoded by the GATA2 gene, a gene which often suffers germline and somatic mutations which lead to a wide range of familial and sporadic diseases, respectively. The gene and its product are targets for the treatment of these diseases.

Inactivating mutations of the GATA2 gene cause a reduction in the cellular levels of GATA2 and the development of a wide range of familial hematological, immunological, lymphatic, and/or other disorders that are grouped together into a common disease termed GATA2 deficiency. Less commonly, these disorders are associated with non-familial (i.e. sporadic or acquired) GATA inactivating mutations. GATA2 deficiency often begins with seemingly benign abnormalities but if untreated progresses to life-threatening opportunistic infections, virus-induced cancers, lung failure, the myelodysplastic syndrome (i.e. MDS), and/or acute myeloid leukemia, principally acute myeloid leukemia (AML), less commonly chronic myelomonocytic leukemia (CMML), and rarely a lymphoid leukemia.

Overexpression of the GATA2 transcription factor that is not due to mutations in the GATA2 gene appears to be a secondary factor that promotes the aggressiveness of non-familial EVI1 positive AML as well as the progression of prostate cancer.